PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer.

Drewett, Lynsey, Lucey, Rebecca, Pinilla, Karen Andrea · Journal of Clinical Oncology · 2022